{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:10:15Z","timestamp":1784740215497,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2504701"],"award-info":[{"award-number":["2022YFC2504701"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425050"],"award-info":[{"award-number":["82425050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002903"],"award-info":[{"award-number":["82002903"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jdermsci.2025.04.010","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:57:41Z","timestamp":1745467061000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overexpression of FOXM1 drives mycosis fungoides progression by regulating the cell cycle"],"prefix":"10.1016","volume":"118","author":[{"given":"Kecen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9616","key":"10.1016\/j.jdermsci.2025.04.010_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and Sezary syndrome","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jdermsci.2025.04.010_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.hoc.2018.09.001","article-title":"Mycosis fungoides and sezary syndrome: an update","volume":"33","author":"Larocca","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.jdermsci.2025.04.010_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"31","key":"10.1016\/j.jdermsci.2025.04.010_bib4","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.jdermsci.2025.04.010_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215512","article-title":"Targeted deep sequencing of mycosis fungoides reveals intracellular signaling pathways associated with aggressiveness and large cell transformation","volume":"13","author":"Wobser","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.jdermsci.2025.04.010_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.jdermsci.2025.04.010_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.17458","article-title":"How we treat advanced stage cutaneous T-cell lymphoma \u2013 mycosis fungoides and Sezary syndrome","volume":"195","author":"Sethi","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.jdermsci.2025.04.010_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14728222.2020.1727888","article-title":"FOXM1: a potential therapeutic target in human solid cancers","volume":"24","author":"Borhani","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jdermsci.2025.04.010_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","article-title":"FOXM1: a small fox that makes more tracks for cancer progression and metastasis","volume":"92","author":"Khan","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.jdermsci.2025.04.010_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12964-018-0266-6","article-title":"Regulation of the master regulator FOXM1 in cancer","volume":"16","author":"Liao","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.jdermsci.2025.04.010_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2023.10.001","article-title":"In vitro evaluation of Neosetophomone B inducing apoptosis in cutaneous T cell lymphoma by targeting the FOXM1 signaling pathway","author":"Kuttikrishnan","year":"2023","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2025.04.010_bib12","article-title":"PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma","author":"Liu","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jdermsci.2025.04.010_bib13","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jdermsci.2025.04.010_bib14","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2025.04.010_bib15","article-title":"Dual role of EZH2 in cutaneous anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment","author":"Yi","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.jdermsci.2025.04.010_bib16","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jid.2017.02.980","article-title":"BCL11B-mediated epigenetic repression is a crucial target for histone deacetylase inhibitors in cutaneous T-cell lymphoma","volume":"137","author":"Fu","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2025.04.010_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2018.02.028","article-title":"SATB1 defines a subtype of cutaneous CD30+ lymphoproliferative disorders associated with a T-helper-17 cytokine profile","author":"Sun","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2025.04.010_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jid.2020.05.120","article-title":"Differential SATB1 expression reveals heterogeneity of cutaneous T-cell lymphoma","volume":"141","author":"Gao","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.jdermsci.2025.04.010_bib19","doi-asserted-by":"crossref","first-page":"adv00613","DOI":"10.2340\/actadv.v101.570","article-title":"High expression of IKZF2 in malignant T cells promotes disease progression in cutaneous T cell lymphoma","volume":"101","author":"Xu","year":"2021","journal-title":"Acta Derm. Venereol."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.04.010_bib20","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/jid.2012.13","article-title":"Molecular markers of early-stage mycosis fungoides","volume":"132","author":"Zhang","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.jdermsci.2025.04.010_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12071582","article-title":"TOX expression in mycosis fungoides and sezary syndrome","volume":"12","author":"Pileri","year":"2022","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.jdermsci.2025.04.010_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjd.21063","article-title":"Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome","volume":"187","author":"Di Raimondo","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2025.04.010_bib23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2025.04.010_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2003.132","article-title":"Thymus and activation-regulated chemokine (TARC\/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides","volume":"48","author":"Kakinuma","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2025.04.010_bib25","unstructured":"Primary cutaneous T-cell lymphoma Part II. Prognosis, management, and future directions, JAM Acad. Dermatol., 2014."},{"issue":"7","key":"10.1016\/j.jdermsci.2025.04.010_bib26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-18-0709","article-title":"The FOXM1 inhibitor RCM-1 decreases carcinogenesis and nuclear beta-catenin","volume":"18","author":"Shukla","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.jdermsci.2025.04.010_bib27","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41419-021-04434-9","article-title":"FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.04.010_bib28","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s10238-023-01037-w","article-title":"The role of FoxM1 in immune cells","volume":"23","author":"Zheng","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"14","key":"10.1016\/j.jdermsci.2025.04.010_bib29","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2020009655","article-title":"Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2025.04.010_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111259","article-title":"Hypermethylation and low expression of FOXM1 predisposes women to unexplained recurrent miscarriage by impairing trophoblast stem cell proliferation","volume":"121","author":"Jiang","year":"2024","journal-title":"Cell Signal."},{"issue":"1","key":"10.1016\/j.jdermsci.2025.04.010_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13062-024-00540-8","article-title":"Biochemical characterization of the feedforward loop between CDK1 and FOXM1 in epidermal stem cells","volume":"19","author":"Polito","year":"2024","journal-title":"Biol. Direct"},{"key":"10.1016\/j.jdermsci.2025.04.010_bib32","doi-asserted-by":"crossref","first-page":"8704","DOI":"10.1038\/ncomms9704","article-title":"POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jdermsci.2025.04.010_bib33","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41388-021-01661-4","article-title":"MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma","volume":"40","author":"Ke","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jdermsci.2025.04.010_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7471","article-title":"Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia","volume":"6","author":"Buchner","year":"2015","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jdermsci.2025.04.010_bib35","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/j.apsb.2022.05.021","article-title":"Cucurbitacin B-induced G2\/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway","volume":"12","author":"Wei","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.jdermsci.2025.04.010_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166698","article-title":"RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer","volume":"8","author":"Zhang","year":"2023","journal-title":"JCI Insight"},{"issue":"475","key":"10.1016\/j.jdermsci.2025.04.010_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aai8583","article-title":"The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice","volume":"10","author":"Sun","year":"2017","journal-title":"Sci. Signal."},{"issue":"13","key":"10.1016\/j.jdermsci.2025.04.010_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136685","article-title":"The anticancer effects of FDI-6, a FOXM1 inhibitor, on triple negative breast cancer","volume":"22","author":"Ulhaka","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:11:11Z","timestamp":1762319471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181125000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0923181125000660"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.04.010","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpression of FOXM1 drives mycosis fungoides progression by regulating the cell cycle","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}